I can answer your question Top
Even this year the MNS booked revenue will be low, only supporting quite a low SP at a very high PE (its higher than what i predicted at the moment beause people are sort of pricing in future growth/revenue now).
But, next year and the year after is when things look like getting a lot better. Its still a med term play 2-3 years, I'm picking early 2023 until $1 which is fine, either way it will be an interesting year.
I am not pricing in a couple of bucks per share until 2024-25 as the revenue looks too low for a few years based on what good old Franky has to say
But the market will have a different outlook to my spreadsheet I'm sure.
Mel
- Forums
- ASX - By Stock
- MNS
- General Discussion Topics
General Discussion Topics, page-3602
-
- There are more pages in this discussion • 4,797 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MNS (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.37M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MNS (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online